Cure8 research brief
Lowering the CRP cutoff could help hospitals identify hospitalized UC patients at higher risk of needing surgery who are currently classified as less severe. That may affect monitoring and treatment decisions during admission.
Clinicians managing hospitalized UC patients, gastroenterology teams, and adult patients and caregivers concerned about inpatient disease severity and surgery risk.
This study of 503 hospital admissions for acute ulcerative colitis (2015–2024) compared patients meeting the traditional Truelove and Witts criteria for severe UC (ASUC) with those who did not (NASUC). About 29% of admissions were NASUC, most commonly high stool frequency without systemic toxicity.
When the CRP cutoff was lowered to ≥12 mg/L, 26% of NASUC cases would be reclassified as ASUC and this change would have identified 43% of patients who later needed colectomy within one year. The authors used propensity score matching to compare colectomy risk while adjusting for gender, endoscopic severity, disease extent, and therapies on admission.
After matching there was no significant difference in colectomy rates between ASUC and NASUC at 30, 90 days, or one year, suggesting NASUC inpatients can carry similar surgical risk as ASUC when objective severity and treatments are similar.
Implications are that a lower CRP threshold may improve detection of high‑risk hospitalized UC patients who are currently missed by standard criteria. This is an abstract‑level report from Alimentary Pharmacology & Therapeutics and summarizes the study methods and findings without providing full trial datasets or external validation.
Keep reading the full paper or guidelines to see how (or whether) this CRP threshold should change clinical practice.
This classification is based on the article abstract; it is not a guideline. The finding comes from a single tertiary centre retrospective cohort with propensity matching; external validation and prospective study would be needed before changing standard diagnostic criteria or protocols.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Bowel urgency is a common, disruptive UC symptom; this trial analysis shows urgency improvements with etrasimod track with clinical remission, endoscopic improvement, better quality of life, and lower inflammatory...
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
